Treace Medical Concepts, Inc. (TMCI)
Nasdaq · Healthcare · Medical Devices
$4.48+2.05%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $291M
- 52-week range
- $1.17 – $7.08
- 52-week change
- −30.32%
- EPS (trailing)
- −$0.92
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $213M (+1.59%)
- Net income
- −$59.0M
- Operating margin
- −25.5%
- Diluted EPS
- −$0.93
- Free cash flow
- −$29.5M
From the company’s annual report on SEC EDGAR.
About Treace Medical Concepts, Inc.
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant.
Headquarters: Ponte Vedra, United States · 450 employees · treace.com